Kiniksa price target raised to $58 from $53 at Wedbush

Wedbush raised the firm’s price target on Kiniksa (KNSA) to $58 from $53 and keeps an Outperform rating on the shares. The firm notes Arcalyst heads into Q1 earnings with continued commercial momentum following a strong FY25, where revenue of $677.6M trounced initial guidance of $560M-$580M, driven by expansion in prescriber breadth and repeat writers, longer duration of therapy, and increasing earlier-line uptake. For FY26, Wedbush estimates Arcalyst revenue of $911M, at the midpoint of guidance, driven by continued prescriber expansion, increasing repeat utilization and sustained penetration into the addressable RP population, supporting a clear path towards $1B-plus in annual sales.